Literature DB >> 8443380

Zinc protoporphyrin in anemia of chronic disorders.

J Hastka1, J J Lasserre, A Schwarzbeck, M Strauch, R Hehlmann.   

Abstract

Hematofluorometric determination of zinc protoporphyrin (ZPP) is a screening method for the assessment of iron deficiency (ID). Chronic disorders are frequently accompanied by anemias of unclear origin, most probably caused by an impairment of iron metabolism. We investigated the relevance of ZPP for the detection of derangements of iron metabolism in anemias of chronic disorders (ACD). In 19 patients with ACD caused by chronic inflammatory non-neoplastic diseases, ZPP was determined and correlated with ferritin, transferrin saturation, and hemoglobin (Hb). Marrow sideroblast counts and semiquantitative grading of the marrow hemosiderin were performed in all patients to exclude ID and to show the decreased iron bioavailability. In all ACD patients who exhibited the typical laboratory findings of disturbed iron metabolism, such as hypoferremia, decreased transferrin saturation, decreased bone marrow sideroblasts, and increased marrow hemosiderin, strongly elevated ZPP levels were found (131 +/- 23 mumol/mol heme). ZPP returned to normal after successful treatment of the underlying disease. This is shown in three patients with polymyalgia rheumatica. We conclude that the fluorometric determination of ZPP allows detection and quantification of derangements of iron metabolism associated with chronic inflammatory disorders. By recording the derangements quantitatively, ZPP allows monitoring of therapy of chronic inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443380

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Investigating iron status in microcytic anaemia: zincprotoporphyrin and soluble transferrin receptor have a role.

Authors:  Anastasios Koulaouzidis; Shivaram Bhat
Journal:  BMJ       Date:  2006-11-04

2.  High levels of zinc-protoporphyrin identify iron metabolic abnormalities in pulmonary arterial hypertension.

Authors:  Ilka Decker; Sudakshina Ghosh; Suzy A Comhair; Samar Farha; Wai Hong Wilson Tang; Margaret Park; Sihe Wang; Alan E Lichtin; Serpil C Erzurum
Journal:  Clin Transl Sci       Date:  2011-08       Impact factor: 4.689

3.  Zinc porphyrins: potent inhibitors of hematopoieses in animal and human bone marrow.

Authors:  J D Lutton; N G Abraham; G S Drummond; R D Levere; A Kappas
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 4.  Heme biosynthesis and the porphyrias.

Authors:  John D Phillips
Journal:  Mol Genet Metab       Date:  2019-04-22       Impact factor: 4.797

5.  Pitfalls in Erythrocyte Protoporphyrin Measurement for Diagnosis and Monitoring of Protoporphyrias.

Authors:  Eric W Gou; Manisha Balwani; D Montgomery Bissell; Joseph R Bloomer; Herbert L Bonkovsky; Robert J Desnick; Hetanshi Naik; John D Phillips; Ashwani K Singal; Bruce Wang; Sioban Keel; Karl E Anderson
Journal:  Clin Chem       Date:  2015-10-19       Impact factor: 8.327

6.  Mu opioid receptor knockout mouse: Phenotypes with implications on restless legs syndrome.

Authors:  Shangru Lyu; Mark P DeAndrade; Erica L Unger; Stefan Mueller; Alexander Oksche; Arthur S Walters; Yuqing Li
Journal:  J Neurosci Res       Date:  2020-05-19       Impact factor: 4.164

Review 7.  Erythroid heme biosynthesis and its disorders.

Authors:  Harry A Dailey; Peter N Meissner
Journal:  Cold Spring Harb Perspect Med       Date:  2013-04-01       Impact factor: 6.915

Review 8.  Iron sequestration and anemia of inflammation.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Semin Hematol       Date:  2009-10       Impact factor: 3.851

9.  [Iron deficiency anemia and anemia of chronic disorders].

Authors:  G Metzgeroth; J Hastka
Journal:  Internist (Berl)       Date:  2015-09       Impact factor: 0.743

10.  Improved method for assessing iron stores in the bone marrow.

Authors:  K S Phiri; J C J Calis; D Kachala; E Borgstein; J Waluza; I Bates; B Brabin; M Boele van Hensbroek
Journal:  J Clin Pathol       Date:  2009-08       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.